Bloomsbury’s FY26 stays on track as Sarah J. Maas sets up a blockbuster FY27
Bloomsbury Publishing has delivered a neat one-two for investors: a steady trading update for the year just ended and a powerful catalyst for the year ahead. The headline is simple. FY 2025/26 profit is in line with expectations, while FY 2026/27 is now expected to be materially ahead of market consensus, thanks to two newly announced Sarah J. Maas novels landing within the next financial year.
For context, Sarah J. Maas – whose ACOTAR universe has been a sales juggernaut – will publish new entries on 27 October 2026 and 12 January 2027. Both fall squarely in Bloomsbury’s financial year to 28 February 2027, setting up a commercial sweet spot across peak retail periods.
Why the ACOTAR dates matter for Bloomsbury’s guidance
Publishing two front-list novels from a top-tier author just 11 weeks apart is rare. Nigel Newton, Bloomsbury’s CEO, calls it “almost unprecedented in publishing history” – and he is not overselling the potential impact. Maas was the highest selling author in the United States in 2024 (Circana) and the No.1 bestselling Fantasy author in the UK in 2025. All 16 of her previous novels are published by Bloomsbury.
Stack those credentials against the timing and you can see why FY27 guidance steps up. One release hits late October, capturing the Christmas build-up, followed by a mid-January drop that benefits from both carry-over momentum and new-year retail space. Pre-orders, backlist sales uplift, and global fan engagement typically cluster around launches like these.
Trading update: steady FY26, stronger FY27
Bloomsbury says group profit for FY 2025/26 (year ended 28 February 2026) will be in line with market consensus. The company flags a strong performance from the Academic division and credits its “portfolio of portfolios” strategy – essentially diversification across divisions, formats and authors – for resilience.
For FY 2026/27, the company now expects group profit to be materially ahead of market consensus. “Materially ahead” is City shorthand for a meaningful beat rather than a marginal one, though Bloomsbury has not quantified the uplift.
What “market consensus” means here
Market consensus is the company’s view of the average analyst forecast. Bloomsbury has put the relevant figures on the record:
| Metric | Consensus (pre-announcement) | Company comment |
|---|---|---|
| FY 2025/26 profit before taxation and highlighted items | £44.3m | In line |
| FY 2026/27 profit before taxation and highlighted items | £44.5m | Now expected to be materially ahead |
| ACOTAR new novel release dates | 27 Oct 2026 and 12 Jan 2027 | Both fall in FY 2026/27 |
Commercial read-through: what could drive the uplift
We do not have unit forecasts or print-run details – not disclosed – but we do have powerful signals. Maas’s sales momentum, the compressed release window, and the dual-peak retail timing together improve the odds of outsized front-list performance and a halo effect on the backlist. Bloomsbury also highlights the Academic division as strong in FY26, offering ballast if trade publishing gets bumpy.
The bigger strategic point is that Bloomsbury’s diversified portfolio has carried FY26 to plan, while a single author’s event releases can tilt FY27 meaningfully higher. That blend – a steady academic engine with hit-driven trade upside – is what management means by a “portfolio of portfolios”.
Positives, watch-outs and what comes next
Reasons to be cheerful
- Two ACOTAR novels within 11 weeks is a rare and potent sales catalyst.
- Both titles land inside FY27, neatly aligning creative output with financial guidance.
- FY26 is in line, suggesting operational discipline and helpful diversification.
- Academic division flagged as strong – an important counterweight to trade cyclicality.
- Author momentum is proven: highest selling author in the US in 2024 and UK No.1 Fantasy in 2025.
Key uncertainties to keep in mind
- Bloomsbury has not quantified how far “materially ahead” goes, so the size of the beat is unknown.
- Execution risks always exist around major releases – supply chain, printing, and timing – though none are flagged.
- Concentration risk is implicit when a single franchise drives guidance upgrades, even within a diversified group.
Milestones and catalysts to watch
- Preliminary Results on 20 May 2026 – expect more colour on trading and possibly FY27 phasing.
- Pre-order traction and retailer placement in the run-up to October 2026 – not disclosed today, but likely to be important.
- Any updates on marketing plans and international roll-out – not disclosed in this RNS.
My take: a textbook set-up for FY27 with credible support in FY26
This is a tidy update. FY26 lands where the market expects at £44.3m profit before tax and highlighted items, underpinned by the Academic division. The bigger news is the ACOTAR double-drop inside FY27, which now takes the company “materially ahead” of the pre-RNS £44.5m consensus.
Could this be conservative? Possibly. The timing straddles both Christmas and the new-year retail window, and Maas’s track record is exceptional. But without disclosed numbers, it is sensible to take the company’s language at face value and wait for May’s prelims to sharpen the range.
Net-net, Bloomsbury is signalling confidence built on two pillars: a resilient base and genuine hit potential. If execution stays tight, FY27 could be a standout year.
Essential details at a glance
- FY 2025/26 outcome: in line with market consensus of £44.3m profit before tax and highlighted items.
- FY 2026/27 outlook: now expected to be materially ahead of consensus of £44.5m.
- Sarah J. Maas ACOTAR releases: 27 October 2026 and 12 January 2027.
- Academic division: strong performance noted in FY26.
- Preliminary Results: scheduled for 20 May 2026.
- Inside information: this announcement is designated as such under MAR.
